Potassium Risk Calculator for ACE Inhibitors and ARBs
Personal Information
When doctors prescribe blood pressure meds, they often choose between ACE inhibitors and ARBs. Both work on the same system in your body-the renin-angiotensin system-to lower blood pressure and protect your kidneys and heart. But they’re not the same. And mixing them? That’s where things get risky.
How ACE Inhibitors and ARBs Work
ACE inhibitors like lisinopril, enalapril, and ramipril stop your body from making angiotensin II, a chemical that tightens blood vessels and raises blood pressure. They do this by blocking the enzyme that turns angiotensin I into angiotensin II. Simple enough.
ARBs-losartan, valsartan, irbesartan-take a different route. Instead of stopping angiotensin II from being made, they block its receptors. Think of it like locking the door so angiotensin II can’t get in, even if it’s still around.
This small difference matters. ACE inhibitors can cause a buildup of bradykinin, which leads to a dry, annoying cough in 10-15% of people. ARBs don’t do that. That’s why if you can’t tolerate an ACE inhibitor, your doctor will switch you to an ARB. It’s the go-to alternative.
Why People Think About Combining Them
It makes sense on paper. If one drug blocks angiotensin II in one way, and another blocks it in another, wouldn’t two be better than one? Especially if you have diabetes and kidney disease, where protein in the urine (proteinuria) is a big problem?
Some studies did show that combining them lowered blood pressure by another 3-5 mmHg and cut proteinuria by about 25%. That sounds great-until you look at what else happens.
The Real Danger: Hyperkalemia and Kidney Damage
The biggest problem with mixing ACE inhibitors and ARBs is hyperkalemia-dangerously high potassium levels. Your kidneys normally flush out extra potassium. But both drugs reduce the hormone that tells your kidneys to do that. When you take both, your potassium can climb fast.
In the ONTARGET trial, which followed over 25,000 high-risk patients, those on both drugs had a 5.5% chance of developing severe hyperkalemia compared to 2.5% on just an ACE inhibitor. That’s more than double. And it’s not just numbers. High potassium can cause irregular heartbeats, muscle weakness, even cardiac arrest.
Then there’s kidney damage. The same trial found that 2.3% of patients on the combo needed dialysis because their kidneys failed. That’s more than twice the rate of those on ACE inhibitors alone. The VA NEPHRON-D trial confirmed this: combining the two increased serious kidney events by 27% without improving survival or heart outcomes.
Real-world data backs this up. A nephrologist at Massachusetts General Hospital stopped the combo in 87% of her patients with diabetic kidney disease because of rising potassium or dropping kidney function. Medical residents on Reddit reported seeing hospitalizations for hyperkalemia linked to this combo during rotations.
When Is It Ever Okay?
Almost never. Major guidelines from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology all say: avoid combining ACE inhibitors and ARBs outside of clinical trials.
There’s one tiny exception some experts mention: non-diabetic patients with very high proteinuria (over 1 gram per day) who haven’t responded to the highest dose of an ACE inhibitor. Even then, it’s not standard. It requires weekly blood tests, close monitoring, and a clear plan to stop if potassium rises or kidney function dips.
Dr. Srinivasan Beddhu from the University of Utah says this might help in rare cases of focal segmental glomerulosclerosis. But even he warns it’s not for everyone. And in 2023, a survey of 317 primary care doctors found only 11% still used the combo-mostly in those rare cases with monthly labs.
What to Do Instead
If you need stronger blood pressure control or better kidney protection, there are safer options.
- Switch from an ACE inhibitor to an ARB if you have a cough.
- Upgrade your dose-sometimes the problem isn’t the drug, it’s the dose.
- Add a low-dose diuretic like chlorthalidone or indapamide. These help flush out fluid and potassium.
- Consider a mineralocorticoid receptor antagonist like spironolactone (12.5 mg daily). It reduces proteinuria by 30-40% with fewer kidney risks than combining ACE inhibitors and ARBs.
And if you’re on one of these drugs and your blood pressure isn’t controlled? Don’t add the other. Talk to your doctor about newer options like ARNIs (angiotensin receptor-neprilysin inhibitors), which have shown better outcomes in heart failure and are now preferred over dual RAS blockade.
Switching Between Them
If your doctor wants to switch you from an ACE inhibitor to an ARB-or vice versa-don’t just swap them on the same day. You need a washout period.
Most guidelines recommend waiting at least 4 weeks between switching. Why? Because even after you stop one, the drug stays in your system. Starting the other too soon can lead to additive effects, increasing your risk of low blood pressure, kidney problems, or high potassium.
But here’s the problem: only 42% of doctors actually follow this rule, according to a 2022 JAMA Internal Medicine study. If you’re switching, make sure your doctor knows to wait. And if you’re unsure, ask for a blood test two weeks after the switch to check your potassium and kidney function.
Monitoring Is Non-Negotiable
No matter which drug you’re on, you need regular blood tests. The first one should be 1-2 weeks after starting or changing the dose. Then every 3 months if you’re stable.
What to check:
- Serum potassium (normal is 3.5-5.0 mmol/L; above 5.5 is dangerous)
- Serum creatinine (to estimate kidney function)
- eGFR (estimated glomerular filtration rate)
If your potassium goes up by more than 0.5 mmol/L or your creatinine rises by 30%, your doctor needs to adjust your treatment. That’s not a minor bump-it’s a red flag.
Why This Still Happens
Even with all the evidence, some patients still end up on both drugs. Why?
- Doctors might think, “They’re not responding to one, so let’s add another.”
- Patients hear “it lowers proteinuria” and assume it’s a win.
- Some specialists, especially nephrologists, are more tempted to try it in tough cases.
But the data is clear: the risks outweigh the benefits. And with better alternatives available-like ARNIs, SGLT2 inhibitors for diabetes, or newer potassium binders-there’s no reason to take this gamble.
The Bottom Line
ACE inhibitors and ARBs are both powerful, proven tools. But they’re not meant to be used together. The idea that more is better doesn’t apply here. In fact, combining them can be dangerous.
If you’re on one and your blood pressure isn’t under control, don’t reach for the other. Talk to your doctor about dose adjustments, adding a diuretic, or switching to a newer class of drugs.
If you’re already on both, ask: Why? What’s the plan? When was your last potassium test? And if you can’t answer those questions, it’s time to have a serious conversation with your provider.
Your kidneys and your heart don’t need extra stress. They need smart, safe choices.
Can I take an ACE inhibitor and an ARB together for better blood pressure control?
No. Combining ACE inhibitors and ARBs is not recommended. While it may lower blood pressure slightly more, it doubles the risk of hyperkalemia and increases the chance of acute kidney injury. Major guidelines from the AHA, ACC, and ESC strongly advise against this combination due to serious safety risks without proven benefits in survival or heart protection.
Why do ACE inhibitors cause a cough but ARBs don’t?
ACE inhibitors block the enzyme that breaks down bradykinin, a substance that can irritate the airways and cause a dry, persistent cough. ARBs don’t affect bradykinin levels-they only block angiotensin II receptors-so they rarely cause this side effect. About 10-15% of people on ACE inhibitors get the cough; only 3-5% do on ARBs.
What should I do if I’m currently taking both an ACE inhibitor and an ARB?
Don’t stop either medication on your own. Contact your doctor immediately. You may need a blood test to check your potassium and kidney function. Most patients on this combination will be switched to one drug, with alternatives like diuretics or spironolactone added if needed. Your doctor may also consider newer options like ARNIs or SGLT2 inhibitors depending on your condition.
Is it safe to switch from an ACE inhibitor to an ARB?
Yes, switching is common and safe if done correctly. Wait at least 4 weeks after stopping the ACE inhibitor before starting the ARB. This prevents overlapping effects that could cause low blood pressure or kidney stress. Your doctor should check your potassium and creatinine 1-2 weeks after the switch to make sure you’re stable.
Are ARBs safer than ACE inhibitors overall?
ARBs are better tolerated because they don’t cause cough or angioedema as often. However, ACE inhibitors have stronger evidence for reducing death in heart failure. Neither is universally “safer”-it depends on your condition. For example, if you have heart failure with reduced ejection fraction, ACE inhibitors are preferred. If you have a cough or are at high risk for swelling, ARBs are the better choice.
What are the signs I might have high potassium from these drugs?
High potassium often has no symptoms at first. But as it rises, you might feel muscle weakness, fatigue, irregular heartbeat, nausea, or tingling in your hands or feet. In severe cases, it can cause cardiac arrest. Regular blood tests are the only reliable way to catch it early. If you’re on an ACE inhibitor or ARB, get your potassium checked every 3 months-or sooner if your dose changes.
Why were some ARBs recalled in 2018-2020?
Some ARBs like valsartan, losartan, and irbesartan were recalled because they contained trace amounts of nitrosamine impurities-chemicals that could increase cancer risk over long-term exposure. These were manufacturing byproducts, not inherent to the drugs. Most manufacturers fixed their processes by late 2023, and current supplies are considered safe. Always check with your pharmacist if you’re concerned about your specific batch.
Are there any new drugs replacing ACE inhibitors and ARBs?
Yes. ARNIs (like sacubitril/valsartan) are now preferred for heart failure with reduced ejection fraction because they’ve been shown to reduce death and hospitalizations better than ACE inhibitors alone. SGLT2 inhibitors (like dapagliflozin and empagliflozin) are also now recommended for patients with diabetes and kidney disease, even without high blood pressure, because they protect the heart and kidneys. These are replacing the need for risky combinations.
What’s Next?
If you’re managing high blood pressure or kidney disease, your treatment doesn’t have to be stuck in the past. The era of combining ACE inhibitors and ARBs is ending-not because the drugs don’t work, but because we now know safer, more effective ways to protect your body.
Ask your doctor: Is my current plan based on the latest guidelines? Are there newer options I haven’t tried? And most importantly-am I being monitored properly?
Your health isn’t about taking more pills. It’s about taking the right ones-and knowing when to stop.
